Structurally Novel Small Molecule Drugs Outperformed in 2020 – Infographic

Drug Innovation in 2020 infographic

Sixty-five percent of the 31 small molecule drugs approved in 2020 by the FDA were structurally novel, meaning they had at least one new molecular entity (NME) based on a new molecular shape.  

Historically, structurally novel drugs have performed exceptionally well in the market, being over 2 times more likely to become blockbuster drugs as well as over 2.5 times more likely to be designated as breakthrough therapies by the FDA, when compared to other small molecule drugs.  

Download this CAS infographic to see structures and information about these new structurally novel small molecule drugs - and read the related blog "Drugs approved by the FDA in 2020 reflect continuing trend of structural innovation".